Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Airleaf dose-finding study of BI 1291583 in bronchiectasis
2021-003304-41Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of verducatib in bronchiectasis (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Time to first pulmonary exacerbation up to 48 weeks after first drug administration. Started Dec 2021; status: completed.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on 2021-003304-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003304-41.